标题：PCSK9抑制剂与心血管事件关系的研究进展

      作者：周杰 1 综述 陈各才 2 审校    1.大连医科大学研究生院，辽宁 大连 116000；2.南京中医药大学附属泰州市人民医院心血管内科，江苏 泰州 225300

      卷次： 2022年33卷6期

      【摘要】 动脉粥样硬化性心血管疾病(ASCVD)已成为全球居民死亡的主要原因。人体血脂紊乱，特别是低密度脂蛋白胆固醇(LDL-C)的增加，是影响动脉粥样硬化(AS)发生发展的最重要因素。前蛋白转化酶枯草溶菌素9(PCSK9)通过与低密度脂蛋白受体 (LDLR)的结合，减少 LDLR 对血清 LDL-C 的清除。PCSK9 抑制剂，如Alirocumab、Evolocumab和 Inclisiran等，可阻止LDLR降解，促进LDL-C的清除，为改善临床脂质代谢和ASCVD的预后提供了新方法。本文系统性地回顾了PCSK9及其抑制剂的发现和作用机制，并对近年来PCSK9抑制剂与心血管事件关系的临床数据作一综述。
      【关键词】 前蛋白转化酶枯草溶菌素9抑制剂；低密度脂蛋白胆固醇；动脉粥样硬化；心血管事件
      【中图分类号】 R54 【文献标识码】 A 【文章编号】 1003—6350（2022）06—0778—05

Research progress on the relationship between PCSK9 inhibitors and cardiovascular outcomes.
ZHOU Jie 1, CHENGe-cai 2. 1.Graduate School, Dalian Medical University, Dalian 116000, Liaoning, CHINA; 2. Department of CardiovascularMedicine, Taizhou People's Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Taizhou 225300,Jiangsu, CHINA【Abstract】 Atherosclerotic cardiovascular disease (ASCVD) has become the leading cause of death in globalpopulation. Lipid disorders, especially increase of low-density lipoprotein cholesterol (LDL-C), is the most importantfactor affecting the development of atherosclerosis (AS). The proprotein convertase subtilisin/kexin type 9 (PCSK9) canreduce the clearance of serum LDL-C by binding to low density lipoprotein receptor (LDLR). PCSK9 inhibitors, such asalirocumab, evolocumab, inclisiran, can prevent LDLR degradation and promote LDL-C clearance, which provides anew approach to improve metabolism of clinical lipid and prognosis of ASCVD. This article systematically reviews thediscovery and mechanism of PCSK9 and its inhibitors, and presents a review of recent clinical data on the relationshipbetween PCSK9 inhibitors and cardiovascular events.
      【Key words】 PCSK9 inhibitors; Low-density lipoprotein cholesterol (LDL-C); Atherosclerosis; Cardiovascularevents　　　·综述·doi:10.3969/j.issn.1003-6350.2022.06.028基金项目：江苏省卫计委青年医学重点人才项目(编号：QNRC2016510)；江苏省卫计委科研课题(编号：H2018003)